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Summary
Background Herpes zoster can cause rare but serious complications; the frequency
of these complications has not been well described.
Objectives To quantify the risks of acute non-postherpetic neuralgia (PHN) zoster
complications, to inform vaccination policy.
Methods We conducted a cohort study among unvaccinated immunocompetent
adults with incident zoster, and age-, sex- and practice-matched control adults
without zoster, using routinely collected health data from the UK Clinical Practice
Research Datalink (years 2001 to 2018). Crude attributable risks of complications
were estimated as the difference between Kaplan–Meier-estimated 3-month
cumulative incidences in patients with zoster vs. controls. We used Cox models
to obtain hazard ratios for our primary outcomes in patients with and without
zoster. Primary outcomes were ocular, neurological, cutaneous, visceral and zos-
ter-specific complications. We also assessed whether antivirals during acute zoster
protected against the complications.
Results In total 178 964 incident cases of zoster and 1 799 380 controls were
included. The absolute risks of zoster-specific complications within 3 months of
zoster diagnosis were 037% [95% confidence interval (CI) 034–039] for Ramsay
Hunt syndrome, 001% (95% CI 00–001) for disseminated zoster, 004% (95%
CI 003–005) for zoster death and 097% (95% CI 092–100) for zoster hospital-
ization. For other complications, attributable risks were 048% (95% CI 044–
051) for neurological complications, 133% (95% CI 128–139) for ocular com-
plications, 029% (95% CI 026–032) for cutaneous complications and 078%
(95% CI 073–084) for visceral complications. Attributable risks were higher
among patients > 50 years old. Patients with zoster had raised risks of all primary
outcomes relative to controls. Antiviral prescription was associated with reduced
risk of neurological complications (hazard ratio 061, 95% CI 053–070).
Conclusions Non-PHN complications of zoster were relatively common, which may
affect cost-effectiveness calculations for zoster vaccination. Clinicians should be
aware that zoster can lead to various complications, besides PHN.
What is already known about this topic?
• Herpes zoster is typically mild and self-limiting; however, it can cause serious cuta-
neous, visceral, neurological and ocular complications.
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• Some complications lead to severe illness, high healthcare costs and mortality,
while others can seriously affect quality of life.
• Better knowledge of the frequency of, and risk factors for, such zoster complica-
tions would be helpful to inform zoster vaccination policy.
What does this study add?
• In this large cohort study among UK adults with zoster, we found raised risks of
neurological, ocular, cutaneous, visceral and zoster-specific complications in the
3 months after zoster diagnosis.
• Estimated absolute risks attributable to zoster were 048% [95% confidence interval
(CI) 044–051] for neurological complications, 133% (95% CI 128–139) for
ocular complications, 029% (95% CI 026–032) for cutaneous complications and
078% (95% CI 073–084) for visceral complications.
Herpes zoster arises from the reactivation of latent varicella
zoster virus following reduced cell-mediated immunity.1 Zos-
ter is typically mild and self-limiting, but complications can
occur. The most common complication is postherpetic neural-
gia (PHN), pain at the site of the original zoster rash, which
persists beyond rash healing. Risk factors for zoster and PHN
include older age and reduced cell-mediated immunity.1–3 As
well as PHN, serious cutaneous, visceral, neurological and
ocular complications can occur.4 Some lead to severe illness,
high healthcare costs and mortality,5 while others can seri-
ously affect quality of life.
Despite their potential seriousness, our knowledge of the
frequency of, and risk factors for, such zoster complications is
limited. Previous studies have typically been small and
restricted to hospital-diagnosed cases of zoster within limited
age groups.6–10 Larger cohort studies have not included a
comparison group without zoster or have not examined risk
factors for the complications.11,12
Accurate quantification of the burden of rare but severe
complications and their risk factors, and the effectiveness of
antiviral medications could help inform zoster vaccine policy
decisions and clinical decisions regarding antiviral therapy. We
therefore aimed to quantify the relative and absolute risks of
acute complications of zoster within 3 months of diagnosis
and to assess whether these risks varied by age, among unvac-
cinated immunocompetent adults. We also sought to assess
whether antiviral drugs prescribed during acute zoster modify
the risks of these complications.
Patients and methods
Study design and setting
We conducted a matched cohort study using routinely col-
lected, anonymized, primary care data from the UK Clinical
Practice Research Datalink (CPRD), a not-for-profit research
service. CPRD hosts two separate databases, GOLD13 and
Aurum,14 which hold data from practices using two different
IT software systems: Vision, and Egton Medical Information
Systems (EMIS), respectively. The databases are representative
of the UK population13 and together encompass over 35 mil-
lion patients lives. These databases include diagnoses (coded
using Read codes in GOLD; and Read, Systematized Nomen-
clature of Medicine and local EMIS codes in Aurum), prescrip-
tions (coded using British National Formulary codes in GOLD
and the Dictionary of Medicines and Devices in Aurum), refer-
rals and some basic demographic information. Approximately
80% of CPRD GOLD practices within England, and all CPRD
Aurum practices, have linked data from other sources. CPRD
data are supplemented by linked data from Hospital Episodes
Statistics (HES), Office of National Statistics (ONS) death data
and Index of Multiple Deprivation (IMD) data. HES data con-
tain all National Health Service hospital admissions in England
since 1997, including diagnoses [coded using International
Classification of Diseases, 10th Revision (ICD-10)] and proce-
dures codes (Office of Population Censuses and Surveys Classi-
fication of Interventions and Procedures version 4). IMD data
provide quintiles of deprivation based on the patient or prac-
tice postcode. ONS data contain date, place and causes of
death (coded using ICD-10).
Participants
Eligible patients were those in CPRD (GOLD or Aurum data-
bases) with linked HES, ONS and IMD data. Patients had at
least 12 months of follow-up after the start of their research-
standard CPRD follow-up (that is, current registration date in
CPRD Aurum and latest of current registration date and prac-
tice up to standard date in CPRD GOLD).15 Patients with zos-
ter were those with a first-ever record of acute zoster
(including no history of PHN), aged ≥ 18 years at zoster
diagnosis (as zoster is very rare among children) and diag-
nosed between 1 January 2001 and 31 July 2018.
Each patient with zoster was randomly matched to 10
patients without zoster (on age within 1 year, practice and
sex) to ensure sufficiently precise estimates could be achieved.
People not exposed to zoster had to be registered in a practice
at the index date of the case (the incident zoster diagnosis
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date), to have been registered for at least 12 months before
and to have no history of zoster at cohort entry. The unex-
posed cohort was assigned an index date identical to that of
their case. Exposure status was time-varying, so unexposed
patients who were matched to an exposed patient with zoster
could switch to the exposed category if they subsequently
developed zoster. In this situation, the patient was censored as
a control at the date of zoster diagnosis, and contributed
exposed time from their zoster index date, with their own set
of matched patients without zoster. Patients with a history of
moderate or severe immunosuppression at the index date,
defined as a weakened immune system as the result of condi-
tions or medication, were excluded from the study16
(Appendix S1; see Supporting Information).
Variables
The primary exposure, zoster, was identified in CPRD data
and in HES data (all codes listed in Appendix S1; see Support-
ing Information). If zoster was identified in both HES and
CPRD, the earliest recorded zoster diagnosis was used. Hospi-
talizations were considered related to zoster if the zoster diag-
nosis was recorded in the primary diagnosis field of any
hospitalization. A secondary exposure, primary care prescrip-
tion of antivirals within 7 days of zoster diagnosis (given for
the treatment of acute zoster), was identified in CPRD.
Outcomes
We searched for complications in CPRD GOLD and Aurum, as
well as linked HES data (first diagnostic field of any episode).
Detailed definitions of each outcome are provided in
Appendix S1 (see Supporting Information). There were five
primary outcome groups (Table 1): (i) acute neurological
complications (not including PHN or Ramsay Hunt syn-
drome); (ii) cutaneous complications (not including dissemi-
nated zoster); (iii) visceral or systemic complications; (iv)
ocular complications (not including cranial nerve palsies as
these were included within neurological complications) and
(v) zoster-specific outcomes. Secondary outcomes were speci-
fic types of complications, which collectively comprise the pri-
mary outcomes (Table 1). We searched for these outcomes
from the day of zoster diagnosis up to 1 year after zoster.
Complications were selected based on the existing literature
and biological plausibility.
Covariates
Comorbidities included all long-term health conditions that
have been associated with increased risk of zoster and/or
PHN, including liver disease, asthma, chronic kidney disease,
chronic obstructive pulmonary disease, depression, diabetes
and autoimmune disorders (rheumatoid arthritis, systemic
lupus erythematosus or inflammatory bowel disease).
Other covariates included age (< 50 and ≥ 50 years), sex
(male and female), ethnicity (white and not white, from
CPRD and HES data), other health and lifestyle factors (body
mass index and smoking status) and finally socioeconomic sta-
tus (quintiles of the 2015 IMD, using patient IMD and, if
missing, practice IMD).
Statistical analysis
For the main analyses, patient-level data from CPRD GOLD
and Aurum were pooled. The cohort study was restricted to
zoster-unvaccinated person-time. Follow-up started at the
index date (date of zoster diagnosis for the exposed patient
within each matched set) and ended at the earliest of death
date (using ONS date or, if missing, CPRD death date), trans-
fer out of practice, last data collection date, 31 July 2018, the
patient developing an outcome of interest, zoster vaccination
date or 3 months following the index date. Patients contribut-
ing at least 1 day of follow-up were included in the study; a
day was added for patients entering and exiting the study on
the same day, to include patients who present initially with a
zoster-related complication such as ‘zoster encephalitis’.
We used a Kaplan–Meier approach to calculate the cumula-
tive unadjusted incidence of each primary outcome at
3 months, in the exposed and unexposed groups; the differ-
ence in cumulative incidence was the attributable risk.
We used survival analysis to assess the overall association
between zoster and each primary and secondary outcome in
the 3 months following zoster. We fitted Cox models stratified
by matched set, with current age as the underlying timescale,
to obtain hazard ratios (HRs) for our primary outcomes in
patients with and without zoster. Our models adjusted initially
for age and sex, then additional covariates. Relative effect mea-
sures were not calculated for the zoster-specific complications.
We went on to stratify our results by patient-specific charac-
teristics by fitting separate models for patients in each age
Table 1 Zoster complications: the five primary outcomes and the
specific conditions comprising each outcome
Neurological: cranial and peripheral nerve palsies (excluding
Ramsay Hunt syndrome), encephalitis, transverse myelitis,
meningitis, Guillain–Barre syndrome and stroke
Ocular: keratitis, conjunctivitis, iritis, blepharitis, retinitis, optic
neuritis, orbital myositis, scleritis, glaucoma, vision loss or
blindness, nonspecific eye infections
Cutaneous: secondary bacterial skin infection (cellulitis,
necrotizing fasciitis and erysipelas)
Visceral and systemic: pneumonia, hepatitis, pancreatitis, sepsis,
pulmonary embolism, osteomyelitis, pleuritis, peritonitis,
myocardial infarction, myositis, myocarditis, pericarditis and
endocarditis
Zoster-specific complications: Ramsay Hunt syndrome, varicella
zoster virus dissemination, zoster-related mortality (identified
from Office for National Statistics data, defined as any ICD-9 or
ICD-10 code related to zoster recorded as a cause of death),
and zoster-related hospitalization (defined as a zoster code in
the primary field of the first episode)
ICD, International Classification of Diseases.
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group and with long-term health conditions, and tested for
interactions using the likelihood ratio test.
Finally, among only patients with zoster, we assessed the inci-
dence and risk of the outcomes according to whether patients
were given antivirals within 7 days of diagnosis. We excluded
patients whose zoster was diagnosed in HES or had an inpatient
HES visit for zoster within 7 days of diagnosis, as secondary care
antiviral prescriptions may not be recorded in CPRD.
Prespecified sensitivity analysis
We repeated the analysis of the association between zoster and
each primary outcome by study database, and combined the
effect estimates using random effect meta-analysis (i.e. two-
stage individual patient data analysis). We also analysed this
risk of complications in the 0–6 months and 0–12 months
following zoster, in order to confirm the risk of complications
was reduced.
Ethical approval
This study was approved by the Independent Scientific Advi-
sory committee (no. 18_278) and London School of Hygiene
& Tropical Medicine ethics (16227).
Results
The cohort included 178 964 patients with zoster (115 790
from GOLD and 63 174 from Aurum) and 1 799 380 sex-,
age- and practice-matched unexposed patients. Almost 60% of
the final cohort were female and the median age at cohort
entry was 62 years (Table 2). Patients with zoster had a
higher prevalence of medical conditions including depression
(31% vs. 27%), chronic obstructive pulmonary disease
(49% vs. 36%) and chronic kidney disease (77% vs. 60%)
(Table 2). Characteristics of the patients in GOLD and Aurum
were similar in terms of age, socioeconomic status and
comorbidities (Table S1; see Supporting Information). The
mean follow-up time was 88 days (SD 9 days) in the exposed
and in the unexposed.
Table 3 shows the percentage of patients with zoster with
zoster-attributable complications in the 3 months following
diagnosis, overall and by risk group. In total, 048% [95%
confidence interval (CI) 044–051] of patients with zoster
developed neurological complications, 133% (95% CI 128–
139) ocular complications, 029% (95% CI 026–032) cuta-
neous complications and 078% (95% CI 073–084) visceral
complications, attributable to zoster. Regarding the zoster-
specific complications, 037% of patients with zoster devel-
oped Ramsay Hunt syndrome, 001% developed disseminated
zoster, 004% died of zoster and 097% were hospitalized. A
higher proportion of older patients with zoster (≥ 50 years)
developed each primary outcome, compared with younger
patients (< 50 years), aside from Ramsay Hunt syndrome.
Table 4 shows the burden and association with zoster for
each primary outcome among all adults in CPRD GOLD or
Aurum, overall and by age group. The relative risk of each
primary outcome was elevated among all patients with zoster,
compared with patients without zoster. The overall relative
risk was largest for neurological complications (HR 363, 95%
CI 335–394), then ocular (HR 199, 95% CI 192–207),
cutaneous (HR 164, 95% CI 152–177) and visceral compli-
cations (HR 130, 95% CI 125–135). There was strong evi-
dence that the risks varied by age at zoster diagnosis (P-value
for interaction < 0001); the magnitude of the relative risks
Table 2 Baseline characteristics of patients with zoster and matched
patients without zoster in Clinical Practice Research Datalink
(n = 1 978 344) and by individual database
With zoster Without zoster
Number of patients 178 964 (100) 1 799 380 (100)
Database
GOLD 115 790 (647) 1 169 272 (650)
Aurum 63 174 (353) 630 108 (350)
Sex female 105 288 (588) 1 050 183 (584)
Age at cohort entry
(years), median
(IQR)
621 (482–741) 615 (478–730)
Ethnicity
White 120 898 (676) 1 134 593 (631)
Not white 6972 (39) 88 200 (49)
Missing 51 094 (285) 576 587 (320)
Socioeconomic statusa
1 (least deprived) 46 031 (257) 457 150 (254)
2 42 099 (235) 420 621 (234)
3 36 479 (204) 367 608 (204)
4 30 979 (173) 312 014 (173)
5 (most deprived) 23 376 (131) 241 987 (134)
Body mass index category
Underweight 3621 (20) 35 887 (20)
Normal weight 63 049 (352) 615 593 (342)
Overweight 59 671 (333) 576 081 (320)
Obese 38 539 (215) 370 742 (206)
Missing 14 084 (79) 201 077 (112)
Smoking status
Never smoked 64 372 (360) 669 354 (372)
Currently smokes 36 605 (205) 394 526 (219)
Formerly smoked 76 258 (426) 685 093 (381)
Missing 1729 (10) 50 407 (28)
Comorbidity
Liver disease 543 (03) 5461 (03)
Asthma 29 302 (164) 237 518 (132)
Chronic
kidney disease
13 829 (77) 108 374 (60)
Chronic obstructive
pulmonary disease
8747 (49) 65 245 (36)
Depression 5504 (31) 49 097 (27)
Diabetes 16 306 (91) 146 446 (81)
Autoimmune
disordersb
4777 (27) 34 800 (19)
The data are presented as the number (%) unless otherwise sta-
ted. IQR, interquartile range. aMeasured by Index of Multiple
Deprivation score: patient level, or practice level if patient level
unavailable (GOLD, n = 1425). bRheumatoid arthritis, systemic
lupus erythematosus or inflammatory bowel disease.
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were greater in younger patients (< 50 years) than in older
patients. Table S2 (see Supporting Information) shows the
burden and association between zoster and individual condi-
tions making up the composite primary outcomes. Encephali-
tis, meningitis and nerve palsies had the strongest associations
of the neurological conditions (all HRs > 8), and orbital
myositis, iritis and keratitis had strongest associations of the
ocular complications (all HRs > 8).
Table 5 shows the association between antiviral use and
each primary outcome among cases of zoster; 3164 (18%)
patients were dropped from analysis as they might have
received antivirals in hospital. There was good evidence that
patients prescribed antivirals in primary care were at reduced
risk of certain complications, specifically Ramsay Hunt syn-
drome (adjusted HR 052, 95% CI 045–062), zoster hospi-
talization (adjusted HR 062, 95% CI 050–078) and
neurological complications (adjusted HR 061, 95% CI 053–
070), compared with patients with zoster not prescribed
antivirals.
Sensitivity analyses
The associations between zoster and each primary outcome
were very similar in both CPRD GOLD and Aurum, and when
running a two-stage individual patient data meta-analysis
(Table S3; see Supporting Information). The magnitude of
association between zoster and each complication was reduced
in the 0–6 months and 0–12 months following zoster
(Table S4; see Supporting Information).
Discussion
In our cohort study of 178 964 UK adults with zoster, from
CPRD GOLD and Aurum, we found raised risks of neurologi-
cal, ocular, cutaneous, visceral and zoster-specific complica-
tions in the 3 months after zoster diagnosis. Estimated
absolute risks attributable to zoster were 048% (95% CI
044–051) for neurological complications, 133% (95% CI
128–139) for ocular complications, 029% (95% CI 026–
032) for cutaneous complications and 078% (95% CI 073–
084) for visceral complications. The estimated absolute attri-
butable risks of zoster-specific complications were 037% for
Ramsay Hunt syndrome, 001% for disseminated zoster,
004% for death due to zoster and 097% for zoster-related
hospitalization. Younger patients with zoster (< 50 years) had
higher relative risk, but lower absolute risk, of complications
compared with older patients (≥ 50 years). Antiviral use dur-
ing acute zoster appeared to protect against neurological com-
plications, Ramsay Hunt syndrome and hospitalization.
Clinicians should be aware that zoster can lead to various
complications, besides PHN.
The UK zoster vaccine cost-effectiveness analysis estimates
that among those aged > 65 years with zoster, 20% are hospi-
talized and 006% die;17 this is in line with our study, which
estimates that (among patients with zoster aged ≥ 50 years)
13% are hospitalized and 006% die. A study in Germany
using a health insurance database containing nationwide rou-
tine outpatient data found that 41% of immunocompetent
patients with zoster (age ≥ 50 years) developed zoster
encephalitis, zoster meningitis and zoster with other complica-
tions.12 A US population-based study using administrative data
supplemented by medical review reported that 37% of 859
cases of zoster experienced a non-PHN complication; those of
older age and with certain comorbidities (including inflamma-
tory bowel disease, HIV and diabetes) were more likely to
experience complications.18 A recent study among 600
immunocompetent unvaccinated patients with zoster
(age ≥ 50 years), selected from a large healthcare organization
in the USA, found that the proportions of cutaneous, neurolog-
ical and other complications were higher than in our study, at
640%, 077% and 101%, respectively; however, our estimates
fall inside their CIs. This latter study assessed for non-PHN
complications by medical chart review, which may have led to
a higher proportion of complications than in our study.19
Table 3 Overall and age-specific riska of complications (percentage with 95% confidence interval) attributable to zoster, among
immunocompetent patients in the 3 months following zoster
All adults
Age at zoster diagnosis
< 50 years ≥ 50 years
All neurologicalb 048 (044–051) 044 (039–050) 049 (045–053)
All ocular 133 (128–139) 085 (078–094) 150 (144–157)
All cutaneousc 029 (026–032) 020 (016–024) 032 (028–035)
All visceral 078 (073–084) 050 (044–059) 089 (082–096)
Zoster-specific complications
Ramsay Hunt syndrome 037 (034–039) 043 (037–049) 034 (031–037)
Disseminated zoster 001 (000–001) 0 001 (000–001)
Zoster death 004 (003–005) 0 006 (005–007)
Zoster hospitalization 097 (092–100) 035 (030–040) 119 (113–125)
aTotal percentages were calculated using a Kaplan–Meier approach to determine the cumulative incidence of each primary outcome at
3 months, in the exposed and unexposed groups; the difference in cumulative incidence was the attributable risk. bNot including Ramsay
Hunt syndrome or postherpetic neuralgia. cNot including disseminated zoster.
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We found that patients with zoster aged < 50 years had a
greater relative risk of developing complications than
patients ≥ 50 years of age. This is likely because the baseline
rate of such complications in younger populations is much
lower. However, overall the absolute risks of complications
were lower in patients under, compared with over, 50 years
of age.
This is the first large-scale UK-based epidemiological
study examining the risk of non-PHN complications of
zoster using routinely collected health data. Collectively,
rarer zoster complications together mean that around one
in 20 patients with zoster will develop a complication
beyond PHN. Highlighting the risk of complications to the
general public may help increase the uptake of shingles
vaccination, as qualitative research has shown that the per-
ceived severity of a disease influences individuals’ decisions
about whether or not to vaccinate; greater perceived harm
due to the infectious agent is associated with higher vac-
cine uptake.20
Zoster diagnoses in UK primary and secondary care are
based on clinical judgement, without laboratory confirmation,
and have not been validated in CPRD or HES. However, a vali-
dation study of zoster in a primary care setting in the Nether-
lands demonstrated a high positive predictive value of zoster
diagnosis of 91%, when confirmed by the presence of vari-
cella zoster virus antibodies.21
Table 4 Burden and association between zoster and each primary outcome among all immunocompetent adults in Clinical Practice Research
Datalink GOLD or Aurum, overall and by age at zoster diagnosis, in the 3 months following zoster
Zoster, n (%) No zoster, n (%) Age- and sex-adjusted HR (95% CI)a Fully adjusted HR (95% CI)b P-valuec
All neurologicald 1160 (06) 3127 (02) 378 (351–408) 363 (335–394) –
All ocular 4662 (26) 23 079 (13) 208 (201–215) 199 (192–207)
All cutaneouse 1231 (07) 7207 (04) 166 (155–177) 164 (152–177)
All visceral 4719 (26) 33 430 (19) 141 (137–146) 130 (125–135)
By age (years)
All neurologicald
< 50 253 (05) 361 (007) 713 (607–839) 658 (551–785) < 0001
≥ 50 907 (07) 2766 (02) 322 (296–351) 313 (286–344)
All ocular
< 50 650 (13) 2364 (05) 281 (258–307) 257 (234–283) < 0001
≥ 50 4012 (31) 20 715 (16) 197 (190–205) 191 (184–199)
All cutaneouse
< 50 163 (03) 651 (01) 254 (214–302) 244 (203–295) < 0001
≥ 50 1068 (08) 6556 (05) 155 (143–167) 155 (143–168)
All visceral
< 50 635 (13) 3913 (08) 166 (153–181) 153 (139–167) < 0001
≥ 50 4084 (31) 29 517 (23) 137 (132–143) 127 (122–132)
HR, hazard ratio; CI, confidence interval. aCox model with age as the underlying timescale. bAdditionally adjusted for rheumatoid arthritis,
inflammatory bowel disease, systemic lupus erythematosus, socioeconomic status, smoking status, body mass index, depression, asthma,
chronic obstructive pulmonary disorder, chronic kidney disease, liver disease and diabetes. cP-value for interaction. dNot including Ramsay
Hunt syndrome or postherpetic neuralgia. eNot including disseminated zoster.
Table 5 Association between non-postherpetic neuralgia complications within 3 months of zoster diagnosis and antiviral use, among
immunocompetent cases of zoster unlikely to receive antivirals in hospital (n = 175 800)
Given antivirals, n (%) Not given antivirals, n (%) Fully adjusted HR (95% CI)a
Zoster-specific complications
Ramsay Hunt syndrome 281 (03) 359 (05) 052 (045–062)
Disseminated zoster 1 (0001) 2 (0003) 032 (003–362)
Zoster death 22 (002) 10 (001) 244 (081–740)
Zoster hospitalization 189 (02) 180 (03) 062 (050–078)
All neurologicalb 474 (04) 496 (07) 061 (053–070)
All ocular 2762 (26) 1746 (25) 098 (092–104)
All cutaneousc 658 (06) 452 (06) 088 (078–100)
All visceral 2627 (25) 1650 (24) 099 (092–105)
HR, hazard ratio; CI, confidence interval. aCox model with age as the underlying timescale adjusted for sex, rheumatoid arthritis, inflamma-
tory bowel disease, systemic lupus erythematosus, socioeconomic status, smoking status, body mass index, depression, asthma, chronic
obstructive pulmonary disorder, chronic kidney disease, liver disease and diabetes. bNot including Ramsay Hunt syndrome or postherpetic
neuralgia. cNot including disseminated zoster.
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There might be differential misclassification of antiviral
receipt with respect to zoster severity, for example if more
severe cases of zoster are treated within secondary care. Pre-
scription data in secondary care were not available, and
although we removed patients with a zoster-related hospital-
ization within 7 days of zoster diagnosis, misclassification of
antiviral status may lead to those ‘not given’ antivirals repre-
senting more severe cases receiving treatment in hospital.
There was strong evidence that patients given antivirals were
less likely to have a hospitalization for zoster and Ramsay
Hunt syndrome, which may reflect this misclassification.
There may be misclassification of some zoster complica-
tions. We included nonspecific zoster complication codes
(such as encephalitis), potentially overestimating zoster-at-
tributable complications. However, by comparing with a
cohort without zoster we were able to account for the baseline
rate of each complication in the general population. Alterna-
tively, we may have underestimated zoster complications. A
US study comparing zoster complication rates among 1959
patients with zoster obtained from administrative data and
supplemented by medical record review found that adminis-
trative data alone significantly underestimated complication
rates (06% vs. 64%), for all complications besides PHN and
ophthalmic zoster.22 However, only zoster-specific codes were
used to identify complications (specifically ICD-9 codes begin-
ning O.53); our study has supplemented specific zoster codes
with nonspecific zoster codes, and therefore we have made
some progress in improving the estimates of our outcomes.
The Aurum and GOLD databases have some differences,
including how diagnoses are coded and when patients’ fol-
low-up is initiated. However, in sensitivity analyses the find-
ings were very similar in both the CPRD GOLD and Aurum
data, suggesting that combining the databases did not bias our
main analysis.
There is a possibility of uncontrolled confounding in the
comparison of the Kaplan–Meier cumulative incidences, in
which it was not possible to adjust for potential confounders.
However, matching (on age, sex and practice) should have
reduced key differences, and the Cox modelling analysis sug-
gested minimal confounding from other variables, so any
residual confounding is likely to be small.
This study indicates that antivirals may reduce the risk of
developing neurological complications. This supports existing
guidelines to prescribe oral antivirals (aciclovir, valaciclovir
or famciclovir) to those over 50 years of age with zoster.
We know from previous research that oral antivirals are
underprescribed in UK primary care.23 Current cost-effective-
ness analyses for zoster vaccination in the UK account for
PHN and hospitalization for zoster only. Although individual
complications are rare, considered collectively they are not
infrequent, which may mean we are underestimating the
costs of zoster. We would therefore suggest that these non-
PHN complications could be incorporated into future cost-ef-
fectiveness work on zoster vaccinations. The study also high-
lights for clinicians that zoster can lead to various
complications, besides PHN.
In conclusion, we observed clinically significant raised risks
of neurological, ocular, cutaneous, visceral and zoster-specific
complications among patients with zoster, within 3 months of
zoster diagnosis. Including non-PHN complications in cost-ef-
fectiveness models of the zoster vaccine might alter the recom-
mendations, as some complications would have significant
cost implications for the healthcare system, as well as impor-
tant impacts on quality of life. Antiviral use during acute zos-
ter appeared to protect against neurological zoster
complications, an observation that may help encourage general
practitioners to adhere to antiviral prescribing guidelines dur-
ing acute zoster.
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